174 related articles for article (PubMed ID: 16538541)
21. Expression of ezrin, Bcl-2, and Ki-67 in chondrosarcomas.
Söderström M; Palokangas T; Vahlberg T; Böhling T; Aro H; Carpen O
APMIS; 2010 Oct; 118(10):769-76. PubMed ID: 20854471
[TBL] [Abstract][Full Text] [Related]
22. Expression of RUNX3 gene, methylation status and clinicopathological significance in breast cancer and breast cancer cell lines.
Jiang Y; Tong D; Lou G; Zhang Y; Geng J
Pathobiology; 2008; 75(4):244-51. PubMed ID: 18580070
[TBL] [Abstract][Full Text] [Related]
23. Bcl-2 protein expression is associated with p27 and p53 protein expressions and MIB-1 counts in breast cancer.
Tsutsui S; Yasuda K; Suzuki K; Takeuchi H; Nishizaki T; Higashi H; Era S
BMC Cancer; 2006 Jul; 6():187. PubMed ID: 16839413
[TBL] [Abstract][Full Text] [Related]
24. Prognostic significance of E-cadherin and ezrin immunohistochemical expression in prostate cancer.
Musiał J; Sporny S; Nowicki A
Pol J Pathol; 2007; 58(4):235-43. PubMed ID: 18459457
[TBL] [Abstract][Full Text] [Related]
25. Ezrin interacts with cortactin to form podosomal rosettes in pancreatic cancer cells.
Kocher HM; Sandle J; Mirza TA; Li NF; Hart IR
Gut; 2009 Feb; 58(2):271-84. PubMed ID: 18852256
[TBL] [Abstract][Full Text] [Related]
26. Podocalyxin increases the aggressive phenotype of breast and prostate cancer cells in vitro through its interaction with ezrin.
Sizemore S; Cicek M; Sizemore N; Ng KP; Casey G
Cancer Res; 2007 Jul; 67(13):6183-91. PubMed ID: 17616675
[TBL] [Abstract][Full Text] [Related]
27. Alterations in the expression of PDCD4 in ductal carcinoma of the breast.
Wen YH; Shi X; Chiriboga L; Matsahashi S; Yee H; Afonja O
Oncol Rep; 2007 Dec; 18(6):1387-93. PubMed ID: 17982621
[TBL] [Abstract][Full Text] [Related]
28. Cyclin D1 expression is associated with poor prognostic features in estrogen receptor positive breast cancer.
Aaltonen K; Amini RM; Landberg G; Eerola H; Aittomäki K; Heikkilä P; Nevanlinna H; Blomqvist C
Breast Cancer Res Treat; 2009 Jan; 113(1):75-82. PubMed ID: 18240019
[TBL] [Abstract][Full Text] [Related]
29. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
Hussein MR; Abd-Elwahed SR; Abdulwahed AR
Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
[TBL] [Abstract][Full Text] [Related]
30. 4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis.
Rojo F; Najera L; Lirola J; Jiménez J; Guzmán M; Sabadell MD; Baselga J; Ramon y Cajal S
Clin Cancer Res; 2007 Jan; 13(1):81-9. PubMed ID: 17200342
[TBL] [Abstract][Full Text] [Related]
31. Prognostic significance of immunohistochemical expression of ezrin in non-metastatic high-grade osteosarcoma.
Ferrari S; Zanella L; Alberghini M; Palmerini E; Staals E; Bacchini P
Pediatr Blood Cancer; 2008 Apr; 50(4):752-6. PubMed ID: 17886294
[TBL] [Abstract][Full Text] [Related]
32. Altered expression of ezrin in esophageal squamous cell carcinoma.
Zeng H; Xu L; Xiao D; Zhang H; Wu X; Zheng R; Li Q; Niu Y; Shen Z; Li E
J Histochem Cytochem; 2006 Aug; 54(8):889-96. PubMed ID: 16585385
[TBL] [Abstract][Full Text] [Related]
33. Ezrin is a key element in the human vagina.
Fadiel A; Lee HH; Demir N; Richman S; Iwasaki A; Connell K; Naftolin F
Maturitas; 2008 May; 60(1):31-41. PubMed ID: 18486367
[TBL] [Abstract][Full Text] [Related]
34. Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy.
Bartlett JM; Ellis IO; Dowsett M; Mallon EA; Cameron DA; Johnston S; Hall E; A'Hern R; Peckitt C; Bliss JM; Johnson L; Barrett-Lee P; Ellis P
J Clin Oncol; 2007 Oct; 25(28):4423-30. PubMed ID: 17906205
[TBL] [Abstract][Full Text] [Related]
35. Syndecan-1 and syndecan-4 are overexpressed in an estrogen receptor-negative, highly proliferative breast carcinoma subtype.
Baba F; Swartz K; van Buren R; Eickhoff J; Zhang Y; Wolberg W; Friedl A
Breast Cancer Res Treat; 2006 Jul; 98(1):91-8. PubMed ID: 16636895
[TBL] [Abstract][Full Text] [Related]
36. BRCA1 expression in invasive breast carcinomas and clinicopathological correlations.
Comănescu M; Popescu CF
Rom J Morphol Embryol; 2009; 50(3):419-24. PubMed ID: 19690768
[TBL] [Abstract][Full Text] [Related]
37. Phosphorylation of Ser78 of Hsp27 correlated with HER-2/neu status and lymph node positivity in breast cancer.
Zhang D; Wong LL; Koay ES
Mol Cancer; 2007 Aug; 6():52. PubMed ID: 17697330
[TBL] [Abstract][Full Text] [Related]
38. Ezrin in osteosarcoma: comparison between conventional high-grade and central low-grade osteosarcoma.
Park HR; Jung WW; Bacchini P; Bertoni F; Kim YW; Park YK
Pathol Res Pract; 2006; 202(7):509-15. PubMed ID: 16677779
[TBL] [Abstract][Full Text] [Related]
39. Activated Leukocyte Cell Adhesion Molecule (ALCAM) is associated with suppression of breast cancer cells invasion.
Jezierska A; Olszewski WP; Pietruszkiewicz J; Olszewski W; Matysiak W; Motyl T
Med Sci Monit; 2006 Jul; 12(7):BR245-56. PubMed ID: 16810131
[TBL] [Abstract][Full Text] [Related]
40. Intracellular sex hormone-binding globulin (SHBG) in normal and neoplastic breast tissue--an additional marker for hormone dependency?
Meyer S; Brumm C; Stegner HE; Sinnecker GH
Exp Clin Endocrinol; 1994; 102(4):334-40. PubMed ID: 7529185
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
